Verve Therapeutics (VERV) Announces Proposed $200M Share Offering

Verve Therapeutics, Inc. (Nasdaq: VERV) today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock. All of the shares are being offered by Verve. In addition, Verve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan, Jefferies, Guggenheim Securities and William Blair are acting as joint book-running managers for the offering.

You May Also Be Interested In

• Entrata (ENT) files for proposed IPO
• Kazia prices public offering at $15.50 per ADS, eyes $40M in proceeds
• William Blair Starts Reformation Inc (REF) at Outperform